Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingGlobeNewsWire • 1h
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsGlobeNewsWire • 04/10/24
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/04/24
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to BuyZacks Investment Research • 04/03/24
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 03/28/24
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramGlobeNewsWire • 03/05/24
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersGlobeNewsWire • 02/20/24
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 11/09/23
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingGlobeNewsWire • 11/01/23
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceGlobeNewsWire • 10/10/23
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 08/10/23
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 05/29/23
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsGlobeNewsWire • 05/11/23
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/19/23
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral MucositisGlobeNewsWire • 03/27/23
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent DevelopmentsGlobeNewsWire • 03/23/23
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human TrialsGlobeNewsWire • 02/27/23
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to DoxorubicinGlobeNewsWire • 02/14/23
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RITGlobeNewsWire • 01/26/23